Table 1 Baseline characteristics of patients who initiated treatment with saxagliptin or sitagliptin
From: Comparison of charges and resource use associated with saxagliptin and sitagliptin
Before propensity matching | After propensity matching | |||||
|---|---|---|---|---|---|---|
Saxagliptin (n = 8438) | Sitagliptin (n = 23,155) | P value | Saxagliptin (n = 7711) | Sitagliptin (n = 7711) | P value | |
Demographics | ||||||
Age, years, mean (SD) | 54.4 (10.0) | 54.8 (10.6) | 0.001 | 54.53 (9.96) | 54.58 (10.60) | 0.7590 |
Men, % | 56.6 | 55.9 | 0.265 | 56.28 | 56.63 | 0.6610 |
Index year, % | <0.001 | 0.0132 | ||||
2010 | 43.0 | 54.8 | 45.13 | 39.49 | ||
2011 | 57.0 | 45.2 | 54.87 | 60.51 | ||
Comorbidities, % | ||||||
Cardiovascular disease | 20.3 | 21.2 | 0.067 | 20.50 | 19.98 | 0.4228 |
Obesity | 10.5 | 11.1 | 0.194 | 10.58 | 10.47 | 0.8133 |
Dyslipidemia | 71.9 | 67.7 | <0.001 | 71.40 | 72.45 | 0.1466 |
Stroke | 2.9 | 3.3 | 0.126 | 3.00 | 3.00 | 1.000 |
Atherosclerosis | 1.9 | 2.1 | 0.337 | 1.92 | 1.74 | 0.4001 |
Retinopathy | 4.3 | 4.6 | 0.189 | 4.45 | 4.38 | 0.8446 |
Hypertension | 69.7 | 66.1 | <0.001 | 68.88 | 70.35 | 0.0459 |
Nephropathy | 2.5 | 2.7 | 0.305 | 2.48 | 2.54 | 0.7969 |
Diabetic foot problems | 0 | 0 | 0.432 | 0.03 | 0.03 | 1.000 |
Neurological complications | 5.5 | 5.4 | 0.763 | 5.38 | 5.45 | 0.8588 |
Dental disease | 0.1 | 0.1 | 0.754 | 0.08 | 0.06 | 0.7629 |
Renal impairment | 6.9 | 7.3 | 0.315 | 6.87 | 6.94 | 0.8738 |
Psychiatry diagnostic group | 11.0 | 11.6 | 0.147 | 11.18 | 10.43 | 0.1324 |
DCSI 1–4 | 27.4 | 27.1 | 0.624 | 27.45 | 26.91 | 0.624 |
DCSI ≥5 | 4.7 | 5.5 | 0.002 | 4.72 | 4.67 | 0.8790 |
CCI, mean (SD) | 1.66 (1.35) | 1.69 (1.49) | <0.05 | 1.66 (1.35) | 1.67 (1.40) | 0.8292 |
Baseline resource use | ||||||
Copay value for index drug at index date, mean (SD) | 55.3 (34.4) | 35.9 (27.4) | <0.001 | 52.57 (32.64) | 50.39 (33.88) | <0.0001 |
Baseline overall charges (%) | <0.001 | 0.7638 | ||||
Quartile 1 (lowest charges) | 17.7 | 19.2 | 17.66 | 16.95 | ||
Quartile 2 | 28.2 | 26.4 | 28.10 | 28.69 | ||
Quartile 3 | 30.4 | 28.3 | 30.14 | 30.93 | ||
Quartile 4 (highest charges) | 23.7 | 26.1 | 24.10 | 23.43 | ||
Inpatient Hospitalizations, % | ||||||
All | 6.7 | 9.5 | <0.001 | 7.15 | 6.42 | 0.0729 |
Diabetes related | 4.6 | 6.8 | <0.001 | 4.86 | 4.50 | 0.4785 |
Baseline Pharmacotherapy | ||||||
Antidiabetic medications, % yes | 75.9 | 72.1 | <0.001 | 75.70 | 77.46 | 0.0097 |
Antidiabetic medication classes, mean (SD) | 1.32 (1.04) | 1.23 (1.03) | <0.001 | 1.31 (1.04) | 1.34 (1.02) | 0.0476 |
Polytherapy, % | ||||||
Any Polytherapy | 56.3 | 60.8 | <0.001 | 56.45 | 55.48 | 0.2238 |
Biguanides | 48.4 | 53.5 | <0.001 | 48.74 | 46.12 | 0.0011 |
Sulphonylureas | 12.5 | 11.3 | 0.006 | 12.27 | 13.18 | 0.0907 |
Insulin | 4.2 | 4.2 | 0.949 | 4.16 | 4.44 | 0.4045 |
Other Medications, % | ||||||
Antihypertensives | 68.3 | 66.8 | 0.014 | 67.95 | 68.64 | 0.3590 |
Statins | 49.3 | 47.5 | 0.005 | 49.02 | 50.12 | 0.1710 |